Leadership Archive - Page 37 of 79 - Medical Affairs Professional Society

Ann Hartry

August 2, 2022/in Professional Development committee/by Jalene Kaiser

Ann has almost 20 years of experience in Medical Affairs and HEOR with a focus in neurology and psychiatry. She joined Lundbeck in 2014 and is currently the Vice President & Deputy Head Global Value Evidence, leading the development and execution of a strategic approach to evidence generation for the full portfolio of products.

Ann has extensive experience as a member of both Medical Affairs and HEOR field teams. Her experience convinced her of the deep need to develop impactful and rigorous evidence (real world and randomized) to support engagement with external experts of all types to ensure that patients receive the best treatment possible.

Ann holds a Ph.D. in Cognitive Neuroscience. Prior to joining industry, her research focused on studies of depression and attentional mechanisms utilizing dense sensor array EEG. She is married, with two kids in college, and is happiest when exploring the less-traveled backroads of the world.

Kate Bradford

December 28, 2021/in /by

Eric Maiese

June 14, 2024/in Evidence/by Jalene Kaiser

李毅達

August 5, 2022/in LE Taiwan Chinese/by Jalene Kaiser

Jean-Jacques (JJ) Murama

August 15, 2022/in EE San Diego/by Jalene Kaiser

鄭皓軒

October 25, 2022/in taipei-cn, LE Taiwan Chinese/by Jalene Kaiser

回顧近三年疫情帶來的轉變，知識與訊息的傳遞的方法學已不可同日而語；ONO Pharmaceutical與多數跨國藥廠皆積極嘗試用更先進、更有效率的方式分享資訊和收集資料。雖然Digital Solution以儼然成為後疫情時代的顯學，Medical Affairs如何善用數位科技，為疾病診斷及治療創造更多產品價值，已是各大藥廠的一大課題。

Phil Lee

July 29, 2022/in LE Taiwan/by Jalene Kaiser

Kopei Chang

July 29, 2022/in LE Taiwan/by Jalene Kaiser

Kopei joined Amgen in May 2016 and provide leadership for key medical strategies, programs, and activities, and drive the interface with regional and global stakeholders, when Amgen building scientific presence and capabilities in Taiwan. In 2022, Kopei has been over 13 years experience in medical affairs with various roles of strategic advisors, clinical trials, field scientific engagement, medical governance across broad therapeutic areas and 11 years clinical practice at emergency medicine before joining the pharmaceutical industry.

Before joining Amgen, Kopei worked at GlaxoSmithKline during Jan 2009 – Apr 2016, where, as Country Medical Director in Taiwan, he spearheaded medical affairs, clinical operation and regulatory affairs teams. He led GSK Taiwan through the transformation of new external engagement model in the medical team. In a prior role, as Medical Advisor, he set up a team of medical scientific liaison for field scientific engagement at GSK Taiwan and provided expertise in support of respiratory, immunology, dermatology, neuroscience, oncology, metabolic, infection areas.

With a Doctor of Medicine, from National Yang Ming Medical University since 1996, Kopei underwent emergency medicine training, at Linkou Chang Gung Memorial Hospital and clinical practice in emergency and general medicine at Chang Gung Memorial Hospital, Keelung Hospital of MoHW, Mennonite Christian Hospital.

陳建煒

October 25, 2022/in LE Taiwan Chinese/by Jalene Kaiser

Dr. Chan is a physician epidemiologist with more than 30 years of global research experience in academia and private sector. He received medical training at National Taiwan University and advanced training in epidemiology at Harvard School of Public Health. He has served on the faculty at National Taiwan University (NTU) and Harvard School of Public Health and joined the private industry in 2005, subsequently became Chief Scientist of the Epidemiology Unit at Optum. Dr. Chan became a professor at NTU College of Medicine in 2013 and had been Director of the NTU Hospital Clinical Trial Center, Department of Medical Research, and NTU Health Data Research Center. He is transitioning to TriNetX (Vice President for Real World Evidence Consulting). Dr. Chan has authored or co-authored more than 150 peer-reviewed research articles and co-edited a textbook on pharmacoepidemiology. His H-index is 59 according to Google Scholar as of October 2022.

K. Arnold Chan

October 25, 2022/in LE Taiwan/by Jalene Kaiser

Dr. Chan is a physician epidemiologist with more than 30 years of global research experience in academia and private sector. He received medical training at National Taiwan University and advanced training in epidemiology at Harvard School of Public Health. He has served on the faculty at National Taiwan University (NTU) and Harvard School of Public Health and joined the private industry in 2005, subsequently became Chief Scientist of the Epidemiology Unit at Optum. Dr. Chan became a professor at NTU College of Medicine in 2013 and had been Director of the NTU Hospital Clinical Trial Center, Department of Medical Research, and NTU Health Data Research Center. He is transitioning to TriNetX (Vice President for Real World Evidence Consulting). Dr. Chan has authored or co-authored more than 150 peer-reviewed research articles and co-edited a textbook on pharmacoepidemiology. His H-index is 59 according to Google Scholar as of October 2022.

Follow Us